Efficacy of LXR/RXR agonists in ameliorating AD pathology and memory loss in mice is dependent on ABCA1[228], and although not a direct gene target of the LXRs, CSF levels of apoA-I are increased with an oral regimen of an LXR agonist[229]. This evidence concerns the gene APOA1 and Alzheimer disease.